[en] [en] INTRODUCTION: Pregnancies resulting from in vitro fertilisation are associated with an increased risk of developing hypertensive disorders of pregnancy, such as preeclampsia, when compared with naturally conceived pregnancies.
OBJECTIVE: The efficacy of aspirin prophylaxis to reduce the incidence of preeclampsia is well established in naturally conceived pregnancies identified as high risk for developing preeclampsia. However, the efficacy of aspirin to reduce the rate of preeclampsia for all pregnancies resulting from in vitro fertilisation remains uncertain, although in vitro fertilisation conception is a well-known risk factor for preeclampsia. Therefore, the purpose of this scoping review is to provide a comprehensive overview of the current literature regarding the use of low-dose aspirin to prevent hypertensive disorders of pregnancy after in vitro fertilisation.
INCLUSION CRITERIA: This review will identify all peer-reviewed published articles including pregnant women who underwent embryo transfer after in vitro fertilisation and were prescribed low-dose aspirin to reduce the risk of hypertensive disorders of pregnancy.
METHODS: We have devised a comprehensive search strategy to systematically identify pertinent studies published from January 2000 until May 2024, within the Medline (PubMed interface), Embase and Scopus databases. The search strategy is based on the keywords 'aspirin,' 'pregnancy-induced hypertension,' and ('in vitro fertilization' OR 'oocyte donation' OR 'embryo transfer' OR 'donor conception'). Two reviewers will independently screen the titles, abstracts and full-text articles to select the relevant articles, using the Covidence software.
ETHICS AND DISSEMINATION: No patients are involved in this study. This study aims to be published in a peer-reviewed journal and could be presented at a conference.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Collee, Julie ; Université de Liège - ULiège > GIGA > GIGA Cancer ; Citadelle Hospital, Liege, Belgium
Vervier, Julie ; Université de Liège - ULiège > GIGA > GIGA CRC In vivo Imaging - Sleep and chronobiology ; Obstetrics and Gynecology Department, Citadelle Hospital, Liege, Belgium
Vandenput, Sandrina ; Université de Liège - ULiège > CARE "ULiège Library" > ULiège Library : Santé
Chantraine, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques ; Obstetrics and Gynecology Department, Citadelle Hospital, Liege, Belgium
Nisolle, Michelle ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique ; Obstetrics and Gynecology Department, Citadelle Hospital, Liege, Belgium
Henry, Laurie ; Université de Liège - ULiège > Département des sciences cliniques ; Citadelle Hospital, Liege, Belgium
NOEL, Laure ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique (CHR) ; Obstetrics and Gynecology Department, Citadelle Hospital, Liege, Belgium
Language :
English
Title :
Low-dose aspirin prophylaxis to prevent hypertensive disorders of pregnancy after in vitro fertilisation: a scoping review protocol.
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Funding text :
The first author (JC) and the second author (JV) are Medical Doctors Applicant to an MSc and a PhD of the Fonds National de la Recherche Scientifique - FNRS (Belgium) (40017857).
Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol 2013; 209: 544. doi:10.1016/j.ajog.2013.08.019
Sinkey RG, Battarbee AN, Bello NA, et al. Prevention, diagnosis and management of hypertensive disorders of pregnancy: a comparison of international guidelines. Curr Hypertens Rep 2020; 22: 66. doi:10.1007/s11906-020-01082-w
Ford ND, Cox S, Ko JY, et al. Hypertensive disorders in pregnancy and mortality at delivery hospitalization-United States, 2017-2019. MMWR Morb Mortal Wkly Rep 2022; 71: 585-91. doi:10.15585/mmwr.mm7117a1
Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for International practice. Pregnancy Hypertens 2018; 13: 291-310. doi:10.1016/j.preghy.2018.05.004
Magee LA, Brown MA, Hall DR, et al. The 2021 International society for the study of hypertension in pregnancy classification, diagnosis & management recommendations for International practice. Pregnancy Hypertens 2022; 27: 148-69. doi:10.1016/j.preghy.2021.09.008
Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 2012; 36: 56-9. doi:10.1053/j.semperi.2011.09.011
Metoki H, Iwama N, Hamada H, et al. Hypertensive disorders of pregnancy: definition, management, and out-of-office blood pressure measurement. Hypertens Res 2022; 45: 1298-309. doi:10.1038/s41440-022-00965-6
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613-22. doi:10.1056/NEJMoa1704559
Verlohren S, Brennecke SP, Galindo A, et al. Clinical interpretation and implementation of the sFlt-1/Plgf ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens 2022; 27: 42-50. doi:10.1016/j.preghy.2021.12.003
Crandon AJ, Isherwood DM. Effect of aspirin on incidence of pre-eclampsia. The Lancet 1979; 313: 1356. doi:10.1016/S0140-6736(79)91996-2
Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018; 218: 287-93. doi:10.1016/j.ajog.2017.11.561
Choi YJ, Shin S. Aspirin prophylaxis during pregnancy: a systematic review and meta-analysis. Am J Prev Med 2021; 61: e31-45. doi:10.1016/j.amepre.2021.01.032
Duley L, Meher S, Hunter KE, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019; 2019: CD004659. doi:10.1002/14651858.CD004659.pub3
von Versen-Höynck F, Schaub AM, Chi Y-Y, et al. Increased preeclampsia risk and reduced aortic compliance with in vitro fertilization cycles in the absence of a corpus luteum. Hypertension 2019; 73: 640-9. doi:10.1161/HYPERTENSIONAHA.118.12043
Epelboin S, Labrosse J, De Mouzon J, et al. Higher risk of pre-eclampsia and other vascular disorders with artificial cycle for frozen-thawed embryo transfer compared to ovulatory cycle or to fresh embryo transfer following in vitro fertilization. Front Endocrinol 2023; 14: 1182148. doi:10.3389/fendo.2023.1182148
Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009; 24: 147-58. doi:10.1152/physiol.00043.2008
Pereira MM, Mainigi M, Strauss JF. Secretory products of the corpus luteum and preeclampsia. Hum Reprod Update 2021; 27: 651-72. doi:10.1093/humupd/dmab003
Blázquez A, García D, Rodríguez A, et al. Is Oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis. J Assist Reprod Genet 2016; 33: 855-63. doi:10.1007/s10815-016-0701-9
Ishihara O, Jwa SC, Kuwahara A, et al. Assisted reproductive technology in Japan: a summary report for 2018 by the ethics committee of the Japan society of obstetrics and Gynecology. Reprod Med Biol 2021; 20: 3-12. doi:10.1002/rmb2.12358
Wang Y, Guo X, Obore N, et al. Aspirin for the prevention of preeclampsia: a systematic review and meta-analysis of randomized controlled studies. Front Cardiovasc Med 2022; 9: 936560. doi:10.3389/fcvm.2022.936560
Peters M, Godfrey C, McInerney P, et al. Chapter 11: Scoping reviews.. In: Aromataris E, Munn Z, eds. JBI Manual for Evidence Synthesis. 2020: 10.. Available: https://doi.org/10.46658/JBIMES-20-12
Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev 2021; 10: 39. doi:10.1186/s13643-020-01542-z
